Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors

Background: Knowledge of clinical course in advanced jejunoileal neuroendocrine tumors (NETs) is poor. Aim: To investigate progression-free survival (PFS), overall survival (OS), and possible predictors for disease progression (DP) in advanced jejunoileal NETs. Patients and Methods: We carried out a multicenter, retrospective analysis of incoming patients with sporadic advanced jejunoileal NETs. PFS and OS were assessed by Kaplan-Meier analysis. Risk factors for progression were analyzed by the Cox proportional hazards method. Results: Of the 114 patients enrolled, 46.5% had functioning tumors, 93.9% had stage IV disease, and 57.3 and 42.7% were G1 and G2 tumors, respectively. During a median follow-up of 48 months (interquartile range 29–84 months), DP occurred in 61.4% of patients, after 19 months (interquartile range 10–41 months) from diagnosis. Median PFS was 36 months. The 2-year and 5-year PFS were 59 and 33%, respectively, while 5-year OS was 77.5%. Ki67 was the sole strong independent risk factor for unfavorable outcome according to multivariate analysis, being significantly associated with both PFS and OS. Conclusions: DP occurred in the majority of patients with advanced jejunoileal NETs, with median PFS being 36 months. Ki67 was a significant predictor of DP and should be considered in determining appropriate treatments and planning follow-up for these patients.

[1]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[2]  B. Wiedenmann,et al.  Neuroendocrine tumors of midgut and hindgut origin: Tumor‐node‐metastasis classification determines clinical outcome , 2011, Cancer.

[3]  A. Scarpa,et al.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Ellis,et al.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[6]  M. Coleman,et al.  Carcinoid Tumors of the Gastrointestinal Tract: Trends in Incidence in England Since 1971 , 2010, The American Journal of Gastroenterology.

[7]  B. Niederle,et al.  Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.

[8]  R. Salazar,et al.  Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  William Mantovani,et al.  Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients , 2010, Modern Pathology.

[10]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. King,et al.  Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. , 2009, Endocrine-related cancer.

[12]  T. de Baère,et al.  Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. , 2009, Endocrine-related cancer.

[13]  M. Vatn,et al.  Small intestinal neuroendocrine tumors: Prognostic factors and survival , 2009, Scandinavian journal of gastroenterology.

[14]  C. Doglioni,et al.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. , 2009, Human pathology.

[15]  S. Willich,et al.  Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. , 2008, Endocrine-related cancer.

[16]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[17]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Scarpa,et al.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.

[20]  B. Wiedenmann,et al.  Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma , 2007, Neuroendocrinology.

[21]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[22]  B. Diggs,et al.  Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.

[23]  D. Santini,et al.  Endocrine Tumors of the Ileum: Factors Correlated with Survival , 2006, Neuroendocrinology.

[24]  B. Weinhold.  Epigenetics: The Science of Change , 2006, Virchows Archiv.

[25]  M. Falconi,et al.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. , 2005, Endocrine-related cancer.

[26]  W. Hiddemann,et al.  Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  A. Grossman,et al.  The diagnosis and medical management of advanced neuroendocrine tumors. , 2004, Endocrine reviews.

[28]  Lawrence H Schwartz,et al.  A statistical simulation study finds discordance between WHO criteria and RECIST guideline. , 2004, Journal of clinical epidemiology.

[29]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[30]  U. Mansmann,et al.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Åkerström,et al.  Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases , 2002, World Journal of Surgery.

[32]  G. Pelosi,et al.  Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. , 1996, Human pathology.